Author

D. Lucena-Agell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Assay:structural biology· 1

Frequent Co-Authors

M. A. Oliva· 2 shared A. Akhmanova· 1 shared A. Andrieux· 1 shared A. E. Prota· 1 shared A. Rai· 1 shared A. Vernet· 1 shared A.-S. Ribba· 1 shared E. Denarier· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

M. A. Oliva

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structural insight into the stabilization of microtubules by taxanes

A. E. Prota, D. Lucena-Agell, Y. Ma, J. Estevez-Gallego, S. Li, K. Bargsten, F. Josa-Prado, J. M. Andreu, K.-H. Altmann, N. Gaillard, S. Kamimura, T. Muehlethaler, M. A. Oliva, M. O. Steinmetz, W.-S. Fang, J. F. Diaz

This study determines the crystal structures of taxane-tubulin complexes and uses simulations to elucidate how taxanes stabilize microtubules through conformational changes and ligand binding.

bioRxiv · Jul 20, 2021Biophysics

Two antagonistic microtubule targeting drugs act synergistically to kill cancer cells

L. Peronne, E. Denarier, A. Rai, R. Prudent, A. Vernet, P. Suzanne, S. Ramirez-Rios, S. Michallet, M. Guidetti, J. Vollaire, D. Lucena-Agell, A.-S. Ribba, V. Josserand, J.-L. Coll, P. Dallemagne, , L. Lafanechere

The paper identifies Carba1, a microtubule-destabilizing drug, which synergizes with paclitaxel to enhance cancer cell killing in vitro and in vivo.

bioRxiv · Feb 6, 2020Cancer Biology